The acquisition of Biotech International is intended to provide Wright with a complementary extremity product portfolio and to significantly expand Wright’s direct sales channel in France and international distribution network for foot and ankle products.

Wright Medical hasn’t enjoyed the smoothest ride over the past 15 years, a stretch that included a spin-out, debt problems, and a buyout, as well as an IPO. All the while, though, the company has proven to be an innovator in the large joints industries and now—under new CEO Gary Henley—it is establishing itself as a force in the extremities and biomaterials markets.

Summary of recent device mergers and acquisitions, alliances, and financings.